A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress in vivo and in vitro

• Main Authors: Yu-jie Xing (Author), Biao-hu Liu (Author), Shu-jun Wan (Author), Yi Cheng (Author), Si-min Zhou (Author), Yue Sun (Author), Xin-ming Yao (Author), Qiang Hua (Author), Xiang-jian Meng (Author), Jin-han Cheng (Author), Min Zhong (Author), Yan Zhang (Author), Kun Lv (Author), Xiang Kong (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Diabetic cardiomyopathy (DCM) is a serious complication of diabetes mellitus (DM). One of the hallmarks of the DCM is enhanced oxidative stress in myocardium. The aim of this study was to research the underlying mechanisms involved in the effects of dapagliflozin (Dap) on myocardial oxidative stress...